CDT Equity (CDT) Tax Rate (2022 - 2023)
CDT Equity's (CDT) quarterly Tax Rate came in at 162.42% in Q2 2023, down 12860.0% on a YoY basis from N/an in Q2 2022, and down 796.78% quarter-over-quarter from 23.31% in Q1 2023.
Powered by 
Analysis
CDT Equity (CDT) Tax Rate (2022 - 2023) Analysis & Trends
CDT Equity (CDT) has reported Tax Rate for 2 consecutive years, with 162.42% the latest figure, recorded in Q2 2023.
- For the quarter ending Q2 2023, Tax Rate fell 12860.0% year-over-year to 162.42%; the trailing twelve-month figure through Jun 2023 stood at 52.11% (changed N/A YoY), and the FY2022 full-year result was 48.46%, changed N/A from the prior year.
- Tax Rate eased to 162.42% in Q2 2023 per CDT's latest filing, from 23.31% in the prior quarter.
- Across five years, Tax Rate topped out at 43.09% in Q3 2022 and bottomed at 162.42% in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.98 Bn | 621.22 Bn | 17.26 Bn | 17.98% |
| 2 | AbbVie | 446.60 Bn | 440.03 Bn | 12.70 Bn | 15.47% |
| 3 | Merck | 357.75 Bn | 350.61 Bn | 12.21 Bn | -95.75% |
| 4 | Novartis Ag | 267.43 Bn | 259.74 Bn | 11.24 Bn | -23.71% |
| 5 | Pfizer | 156.61 Bn | 144.91 Bn | 10.94 Bn | 62.33% |
| 6 | Sanofi | 52.22 Bn | 44.84 Bn | 10.79 Bn | -31.96% |
| 7 | Revolution Medicines | 42.95 Bn | 42.95 Bn | - | - |
| 8 | Incyte | 24.57 Bn | 20.04 Bn | 1.57 Bn | 22.08% |
| 9 | United Therapeutics | 21.31 Bn | 18.65 Bn | 683.80 Mn | 10.65% |
| 10 | CDT Equity | 182,285.66 | 182,285.66 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -162.42% |
| Mar 31, 2023 | 23.31% |
| Dec 31, 2022 | 25.09% |
| Sep 30, 2022 | 43.09% |
| Jun 30, 2022 | -33.82% |